Drug intelligence / Profile preview

Cytorich

Development stage: Unknown
Lead developer: Institute of Human Mechanics
Modality: Cell Therapies
Administration: Intraarticular

Overview

Cytorich is an autologous blood product (ABP) system developed by Antnor Health for the treatment of knee osteoarthritis. It is prepared using a proprietary kit that processes a patient's own blood to create a concentrated solution of platelets and anti-inflammatory proteins. While similar to standard platelet-rich plasma (PRP), Cytorich is specifically enriched with anti-inflammatory components, such as interleukin-1 receptor antagonist (IL-1Ra), to better address the inflammatory environment of the osteoarthritic joint. The product is administered via intra-articular injection to reduce pain and improve physical function by modulating local inflammation and promoting tissue repair through the delivery of growth factors.

Brand names: Cytorich
Other names: CytoRichCytorich PRP kitAntnor Cytorich

Beyond the preview

Go deeper on Cytorich.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytorich.

Explore the full profile